ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
AbCellera Biologics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Market Cap | $3.66B | $166.30M |
| Enterprise Value | $3.12B | $88.19M |
| PS Ratio | 55.28 | 3.65 |
| PB Ratio | 4.08 | 2.03 |
| P/TBV Ratio | 4.51 | 2.29 |
Enterprise value
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| EV / Sales | 47.12 | 2.51 |
Income (trailing twelve months)
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Revenue | $66.17M | $58.34M |
| Operating Income | -$225.16M | -$21.40M |
| Pretax Income | -$196.77M | -$14.34M |
| Net Income | -$164.66M | -$22.46M |
| EBITDA | -$225.16M | -$16.91M |
| EPS (Diluted) | -$0.54 | -$0.83 |
Margins
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Operating Margin | -340.3% | -44.0% |
| Pretax Margin | -297.4% | -13.3% |
| Profit Margin | -248.8% | -40.2% |
| EBITDA Margin | -340.3% | -30.2% |
| FCF Margin | -180.8% | -9.27% |
Returns
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -17.3% | -53.2% |
| Return on Assets (ROA) | -12.2% | -40.9% |
| Return on Invested Capital (ROIC) | -43.9% | -32.4% |
| Return on Capital Employed (ROCE) | -17.9% | -38.1% |
Growth
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 101.3% | 5.96% |
| Revenue Growth (3Y CAGR) | -46.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -20.3% | 6.48% |
Balance sheet
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $540.10M | $61.43M |
| Net Cash (Debt) | $540.10M | $15.35M |
| Net Cash Per Share | $1.76 | $0.66 |
| Equity (Book Value) | $896.02M | $49.09M |
| Book Value Per Share | $2.92 | $1.37 |
| Tangible Book Value | $811.68M | $23.52M |
| Working Capital | $626.04M | $76.81M |
Financial position
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Current Ratio | 12.77 | 3.34 |
| Quick Ratio | 10.88 | 2.44 |
Cash flow (trailing twelve months)
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Operating Cash Flow | -$94.94M | -$12.35M |
| Capital Expenditures | -$24.73M | -$1.08M |
| Free Cash Flow | -$119.67M | -$20.22M |
| FCF Per Share | -$0.39 | -$0.42 |
Efficiency
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.39 |
| Revenue Per Employee | $117.75K | $404.87K |
| Profits Per Employee | -$292.98K | -$703.34K |
| Employee Count | 562 | 74 |
Dividends and yields
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Earnings Yield | -4.50% | -23.3% |
| FCF Yield | -3.27% | -8.72% |
Shares
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Shares Outstanding | 306,611,000 | 58,127,000 |
| Shares Change (YoY) | 1.74% | 10.9% |
| Shares Change (QoQ) | 0.83% | 0.54% |
| Float | 236,738,000 | 49,136,700 |
| Shares Held by Insiders | 22.8% | 11.6% |
| Shares Held by Institutions | 37.9% | 59.4% |
Taxes
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Income Tax | -$32.11M | $79.87K |
Scores
| Measure | AbCellera Biologics | Industry median |
|---|---|---|
| Altman Z-Score | 5.25 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from AbCellera Biologics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.